C. Janus, J. Pearson, J. Mclaurin, P. M. Mathews, Y. Jiang et al., A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, vol.408, pp.979-982, 2000.

D. Morgan, D. M. Diamond, P. E. Gottschall, K. E. Ugen, C. Dickey et al., A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, vol.408, pp.982-985, 2000.

D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda et al., Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse, Nature, vol.400, pp.173-177, 1999.

S. Gilman, M. Koller, R. S. Black, L. Jenkins, S. G. Griffith et al., Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, pp.1553-1562, 2005.

J. M. Orgogozo, S. Gilman, J. F. Dartigues, B. Laurent, M. Puel et al., Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, vol.61, pp.46-54, 2003.

C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins et al., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial, Lancet, vol.372, pp.216-223, 2008.

B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert et al., Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study, Lancet Neurol, vol.11, pp.597-604, 2012.

M. Farlow, S. E. Arnold, C. H. Van-dyck, P. S. Aisen, B. J. Snider et al., Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement, vol.8, pp.261-271, 2012.

S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann et al., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, Arch Neurol, vol.69, pp.198-207, 2012.

S. Salloway, R. Sperling, S. Gilman, N. C. Fox, K. Blennow et al., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, Neurology, vol.73, pp.2061-2070, 2009.

J. O. Rinne, D. J. Brooks, M. N. Rossor, N. C. Fox, R. Bullock et al., 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study, Lancet Neurol, vol.9, pp.363-372, 2010.

K. Blennow, H. Zetterberg, J. O. Rinne, S. Salloway, J. Wei et al., Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, Arch Neurol, vol.69, pp.1002-1010, 2012.

P. Szabo, N. Relkin, and M. E. Weksler, Natural human antibodies to amyloid beta peptide, Autoimmun Rev, vol.7, pp.415-420, 2008.

R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow et al., Intravenous immunoglobulin for treatment of mild-tomoderate Alzheimer's disease: A Phase 2, randomised, double-blind, placebo-controlled, dose-finding trial, Lancet Neurol, vol.12, pp.233-243, 2013.

F. M. Laferla, K. N. Green, and S. Oddo, Intracellular amyloid-beta in Alzheimer's disease, Nat Rev Neurosci, vol.8, pp.499-509, 2007.

I. Klyubin, D. M. Walsh, C. A. Lemere, W. K. Cullen, G. M. Shankar et al., Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo, Nat Med, vol.11, pp.556-561, 2005.

S. Lesne, M. T. Koh, L. Kotilinek, R. Kayed, C. G. Glabe et al., A specific amyloid-beta protein assembly in the brain impairs memory, Nature, vol.440, pp.352-357, 2006.

I. C. Martins, I. Kuperstein, H. Wilkinson, E. Maes, M. Vanbrabant et al., Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice, EMBO J, vol.27, pp.224-233, 2008.

N. Rudinskiy, J. M. Hawkes, R. A. Betensky, M. Eguchi, S. Yamaguchi et al., Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease, Nat Neurosci, vol.15, pp.1422-1429, 2012.

L. C. Souza, F. Corlier, M. O. Habert, O. Uspenskaya, R. Maroy et al., Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease, Brain, vol.134, pp.2036-2043, 2011.

W. E. Klunk, C. A. Mathis, J. C. Price, B. J. Lopresti, and S. T. Dekosky, Twoyear follow-up of amyloid deposition in patients with Alzheimer's disease, Brain, vol.129, pp.2805-2807, 2006.

E. Callaway, Alzheimer's drugs take a new tack, Nature, vol.489, pp.13-14, 2012.

J. C. Dodart, K. R. Bales, K. S. Gannon, S. J. Greene, R. B. Demattos et al., Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model, Nat Neurosci, vol.5, pp.452-457, 2002.

L. A. Kotilinek, B. Bacskai, M. Westerman, T. Kawarabayashi, L. Younkin et al., Reversible memory loss in a mouse transgenic model of Alzheimer's disease, J Neurosci, vol.22, pp.6331-6335, 2002.

E. B. Lee, L. Z. Leng, B. Zhang, L. Kwong, J. Q. Trojanowski et al., Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, J Biol Chem, vol.281, pp.4292-4299, 2006.

R. A. Sperling, J. Karlawish, and K. A. Johnson, Preclinical Alzheimer disease-the challenges ahead, Nat Rev Neurol, vol.9, pp.54-58, 2012.

C. Toly-ndour, G. Lui, M. M. Nunes, M. Bruley-rosset, A. P. et al., MHC-independent genetic factors control the magnitude of CD4 T cell responses to amyloid-beta peptide in mice through regulatory T cell-mediated inhibition, J Immunol, vol.187, pp.4492-4500, 2011.

G. Dorothee, M. Bottlaender, E. Moukari, L. C. Souza, R. Maroy et al., Distinct patterns of antiamyloid-beta antibodies in typical and atypical Alzheimer disease, Arch Neurol, vol.69, pp.1181-1185, 2012.

X. Huang, A. D. Reynolds, R. L. Mosley, and H. E. Gendelman, CD 4 T cells in the pathobiology of neurodegenerative disorders, J Neuroimmunol, vol.211, pp.3-15, 2009.

T. Wyss-coray, Inflammation in Alzheimer disease: Driving force, bystander or beneficial response, Nat Med, vol.12, pp.1005-1015, 2006.

J. L. Grant, E. E. Ghosn, R. C. Axtell, K. Herges, H. F. Kuipers et al., Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis, Sci Transl Med, vol.4, pp.145-105, 2012.

V. Berg, J. Prokop, S. Miller, K. R. Obst, J. Kalin et al., Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline, Nat Med, vol.18, pp.1812-1819, 2012.

R. O. Weller, D. Boche, and J. A. Nicoll, Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy, Acta Neuropathol, vol.118, pp.87-102, 2009.

D. M. Wilcock and C. A. Colton, Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice, CNS Neurol Disord Drug Targets, vol.8, pp.50-64, 2009.

D. Boche, E. Zotova, R. O. Weller, S. Love, J. W. Neal et al., Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, vol.131, pp.3299-3310, 2008.

N. Melzer, A. Harder, C. C. Gross, J. Wolfer, W. Stummer et al., CD4() T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid betarelated angiitis, Arch Neurol, vol.69, pp.773-777, 2012.

S. Kinkingnehun, M. Sarazin, S. Lehericy, E. Guichart-gomez, T. Hergueta et al., VBM anticipates the rate of progression of Alzheimer disease: A 3-year longitudinal study, Neurology, vol.70, pp.2201-2211, 2008.

C. Bernick, J. Cummings, R. Raman, X. Sun, and P. Aisen, Age and rate of cognitive decline in Alzheimer disease: Implications for clinical trials, Arch Neurol, vol.69, pp.901-905, 2012.

W. D. Knight, A. A. Okello, N. S. Ryan, F. E. Turkheimer, R. Martinez-de-llano et al., Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers, Brain, vol.134, pp.293-300, 2011.

R. A. Sperling, P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.280-292, 2011.

R. S. Desikan, L. K. Mcevoy, W. K. Thompson, D. Holland, J. B. Brewer et al., Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau, Arch Neurol, vol.69, pp.709-713, 2012.

I. Driscoll and J. Troncoso, Asymptomatic Alzheimer's disease: A prodrome or a state of resilience?, Curr Alzheimer Res, vol.8, pp.330-335, 2011.

J. Kipnis, H. Cohen, M. Cardon, Y. Ziv, and M. Schwartz, T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions, Proc Natl Acad Sci U S A, vol.101, pp.8180-8185, 2004.

M. Schwartz and R. Shechter, Systemic inflammatory cells fight off neurodegenerative disease, Nat Rev Neurol, vol.6, pp.405-410, 2010.

A. Boutajangout, D. Quartermain, and E. M. Sigurdsson, Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model, J Neurosci, vol.30, pp.16559-16566, 2010.

X. Chai, S. Wu, T. K. Murray, R. Kinley, C. V. Cella et al., Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression, J Biol Chem, vol.286, pp.34457-34467, 2011.

L. Troquier, R. Caillierez, S. Burnouf, F. J. Fernandez-gomez, M. E. Grosjean et al., Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach, Curr Alzheimer Res, vol.9, pp.397-405, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00664452

K. Rezai-zadeh, D. Gate, G. Gowing, and T. Town, How to get from here to there: Macrophage recruitment in Alzheimer's disease, Current Alzheimer Res, vol.8, pp.156-163, 2011.